3[3]Veneman TF, Tack CJ, van Haeften TW. The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe. Neth-J-Med, 1998,52(5): 179-186.
4[4]Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann-Pharmacother,1998,32(10): 1044-52.
5[5]Cheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.Drugs, 1997,54(3) :355-368.
6[6]Jones RB,Dickinson K,Anthony DM,et al. Evaluation of BIS 67582, a novel antidiabetic agent,in normal and diabetic rats.B.J Pharmacol, 1997,120(6): 1135-1143.
7[1]陈新谦.新编药物学.第14版.北京:人民卫生出版社,1998:318
8[10]Inoue I et al. Acarbose controls postprandial hyper-insulinemia in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Prac,1997,37:129.
9[13]Koltetman O, Schwartz S, Corder C, et al. Effect of 14days'subcutaneous administration of the human amylin analogue,pramlintide(AC137) ,on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia, 1996,39(4): 492-499.
10[17]Mealy N, Castaner J. SDZ-FOX-988, Antidiabetic,Carnitine palmitoyltransferase inhibitor. Drugs Fut, 1996, 21 (3):258-260.
